POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.

被引：0
|
作者：
Li, H. [1 ]
Han, T. H. [2 ]
Hunder, N. [1 ]
Jang, G. [1 ]
Zhao, B. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
[2] Stemcentrx Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-041
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [31] Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate
    Newland, Ashley M.
    Li, Jenny X.
    Wasco, Lindsey E.
    Aziz, May T.
    Lowe, Denise K.
    PHARMACOTHERAPY, 2013, 33 (01): : 93 - 104
  • [32] BRENTUXIMAB VEDOTIN (SGN-35), AN ANTIBODY-DRUG CONJUGATE, DOES NOT AFFECT MIDAZOLAM PHARMACOKINETICS.
    Han, T. H.
    Grove, L. E.
    Lynch, C. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S52 - S52
  • [33] A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis
    Gotlib, Jason
    Baird, John H.
    George, Tracy, I
    Langford, Cheryl
    Reyes, Isabel
    Abuel, Justin
    Perkins, Cecelia
    Schroeder, Kurt
    Bose, Prithviraj
    Verstovsek, Srdan
    BLOOD ADVANCES, 2019, 3 (15) : 2264 - 2271
  • [34] Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas
    Wagner, Sandro M.
    Melchardt, Thomas
    Egle, Alexander
    Magnes, Teresa
    Skrabs, Cathrin
    Staber, Philipp
    Simonitsch-Klupp, Ingrid
    Panny, Michael
    Lehner, Barbara
    Greil, Richard
    Keil, Felix
    Jager, Ulrich
    Sillaber, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (03) : 251 - 258
  • [35] Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis
    Li, Yixue
    Zeng, Ruolan
    Xia, Chen
    Li, Yajun
    He, Yizi
    Wang, Caiqin
    Zhou, Hui
    BLOOD, 2024, 144 : 6465 - 6465
  • [36] Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma
    Viviani, Simonetta
    Guidetti, Anna
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (08) : 841 - 849
  • [37] Anti CD-30 Antibody-Drug Conjugate Brentuximab Vedotin (ADCETRIS®) May Be a Promising Treatment Option for Systemic Mastocytosis (SM).
    Mehta, Amitkumar
    Reddy, Vishnu V. B.
    Borate, Uma
    BLOOD, 2012, 120 (21)
  • [38] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
    Younes, Anas
    Bartlett, Nancy L.
    Leonard, John P.
    Kennedy, Dana A.
    Lynch, Carmel M.
    Sievers, Eric L.
    Forero-Torres, Andres
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1812 - 1821
  • [39] Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation
    Rothe, Achim
    Sasse, Stephanie
    Goergen, Helen
    Eichenauer, Dennis A.
    Lohri, Andreas
    Jaeger, Ulrich
    Bangard, Christopher
    Engert, Andreas
    BLOOD, 2012, 120 (21)
  • [40] Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper
    Zinzani, Pier Luigi
    Corradini, Paolo
    Gianni, Alessandro M.
    Federico, Massimo
    Santoro, Armando
    Vitolo, Umberto
    Barosi, Giovanni
    Tura, Sante
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (09): : 507 - 513
12345